Product Description
It was found to induce antibodies capable of killing a wide range of PNAG-expressing pathogens.
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Alopexx
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Influenza, Human|Pneumonia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02853617 |
AV-101-16 | P2 |
Completed |
Influenza, Human|Pneumonia |
2018-04-23 |
13% |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/10/2024 |
News Article |
Alopexx Announces Collaboration with Bharat Biotech for the Development and Commercialization of Broad-Spectrum Anti-Microbial Vaccine AV0328 |
|
09/06/2024 |
News Article |
Alopexx Announces Investment from Biotech Consortia, Inc. |
|
10/12/2023 |
News Article |
Alopexx to Present Data on F598, a Novel, Broad-Spectrum Immunotherapeutic at IDWeek 2023 |
|
10/11/2023 |
News Article |
Alopexx Announces Presentation at IDWeek 2023 |